Genflow Biosciences Plc (GB:GENF) has released an update.
Genflow Biosciences Plc, a UK-based biotech firm at the forefront of longevity research, has scheduled its Annual General Meeting for 27 June 2024 in London. Shareholders are directed to the company’s website for the AGM Notice and proxy forms, as well as the Annual Report and Accounts for 2023. Genflow is advancing its lead gene therapy compound, GF-1002, to address age-related diseases, with a focus on a prevalent chronic liver condition, and is preparing for clinical trials set to commence in 2025.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
